Jeffrey Immelt, GE’s chairman and CEO, has been busy reshaping the company so that it revolves more around heavy industry, but there appear to be no current plans to sell GE’s life-sciences business.
As reported by Bloomberg Business, GE is actually looking to grow that side of its business, which includes imaging, chromatography, cell-therapy tools, and more.
“It’s a fundamentally attractive industry with growth and we have a very strong competitive position,’’ said John Flannery, president and CEO of GE Healthcare, as quoted by Bloomberg Business. “We are certain this business grows faster inside of GE than it would grow outside.”
Click below for the full text from Bloomberg Business, which also goes on to summarize a lot of key information regarding GE’s continued transformation:
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.